688192 迪哲医药-U
交易中 11-05 14:07:33
资讯
新帖
简况
迪哲医药（688192）11月4日主力资金净卖出403.78万元
证券之星 · 08:32
迪哲医药（688192）11月4日主力资金净卖出403.78万元
迪哲医药（688192）11月2日主力资金净买入3646.14万元
证券之星 · 11-03 08:16
迪哲医药（688192）11月2日主力资金净买入3646.14万元
迪哲医药（688192）披露2026年第三季度报告，10月30日股价上涨0.7%
证券之星 · 10-30
迪哲医药（688192）披露2026年第三季度报告，10月30日股价上涨0.7%
迪哲医药(688192)9月30日股东户数1.34万户，较上期增加3.96%
证券之星 · 10-30
迪哲医药(688192)9月30日股东户数1.34万户，较上期增加3.96%
迪哲医药(688192.SH)发布前三季度业绩，归母净利润36.39亿元
智通财经 · 10-30
迪哲医药(688192.SH)发布前三季度业绩，归母净利润36.39亿元
迪哲医药（688192）10月27日主力资金净卖出2748.95万元
证券之星 · 10-28
迪哲医药（688192）10月27日主力资金净卖出2748.95万元
迪哲医药（688192）10月23日主力资金净卖出1111.93万元
证券之星 · 10-24
迪哲医药（688192）10月23日主力资金净卖出1111.93万元
迪哲医药（688192）10月20日主力资金净卖出1441.66万元
证券之星 · 10-21
迪哲医药（688192）10月20日主力资金净卖出1441.66万元
迪哲医药（688192）10月13日主力资金净买入348.45万元
证券之星 · 10-14
迪哲医药（688192）10月13日主力资金净买入348.45万元
迪哲医药（688192）9月24日主力资金净卖出1437.14万元
证券之星 · 09-25
迪哲医药（688192）9月24日主力资金净卖出1437.14万元
每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%
证券之星 · 09-13
每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%
迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%
证券之星 · 09-10
迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%
迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表
智通财经 · 09-09
迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表
每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理
证券之星 · 09-06
每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
智通财经 · 09-01
迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
证券之星 · 08-31
迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
智通财经 · 08-28
迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资
每周股票复盘：迪哲医药（688192）股东户数增18.73%
证券之星 · 08-23
每周股票复盘：迪哲医药（688192）股东户数增18.73%
迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%
证券之星 · 08-21
迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%
每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人
证券之星 · 08-16
每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人
加载更多
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药-U","latestPrice":67.01,"timestamp":1793858853000,"preClose":64.1,"halted":0,"volume":8728976,"delay":0,"changeRate":0.0454,"floatShares":461000000,"shares":465000000,"eps":7.4268,"marketStatus":"交易中","change":2.91,"latestTime":"11-05 14:07:33","open":63.62,"high":67.51,"low":63.5,"amount":579000000,"amplitude":0.0626,"askPrice":67.08,"askSize":94,"bidPrice":67.01,"bidSize":53,"shortable":0,"etf":0,"ttmEps":7.4268,"tradingStatus":2,"nextMarketStatus":{"tag":"收盘","tradingStatus":0,"beginTime":1793862000000},"marketStatusCode":2,"adr":0,"adjPreClose":64.1,"symbolType":"stock_kcb","openAndCloseTimeList":[[1793842200000,1793849400000],[1793854800000,1793862000000]],"highLimit":70.51,"lowLimit":57.69,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":465165842,"isCdr":false,"pbRate":5.98,"roa":"--","peRate":9.022728,"roe":"115.44%","epsLYR":-1.71,"committee":0.227414,"marketValue":31171000000,"turnoverRate":0.0189,"status":0,"floatMarketCap":30906000000},"requestUrl":"/m/hq/s/688192","defaultTab":"news","newsList":[{"id":"2681097518","title":"迪哲医药（688192）11月4日主力资金净卖出403.78万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2681097518","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2681097518?lang=zh_cn&edition=full","pubTime":"2026-11-05 08:32","pubTimestamp":1793838728,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月4日收盘，迪哲医药报收于64.1元，上涨8.35%，换手率2.0%，成交量9.24万手，成交额5.7亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入6455.94万元，融资偿还3643.29万元，融资净买入2812.65万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110500009906.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1515","09939","BK1161","688192","BK0239","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2680794044","title":"迪哲医药（688192）11月2日主力资金净买入3646.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2680794044","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2680794044?lang=zh_cn&edition=full","pubTime":"2026-11-03 08:16","pubTimestamp":1793664979,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年11月2日收盘，迪哲医药报收于61.07元，上涨9.5%，换手率2.74%，成交量12.62万手，成交额7.38亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入5713.2万元，融资偿还5812.21万元，融资净偿还99.01万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026110300010244.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","688192","09939","BK1574","BK1515","BK0239","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679572243","title":"迪哲医药（688192）披露2026年第三季度报告，10月30日股价上涨0.7%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679572243","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679572243?lang=zh_cn&edition=full","pubTime":"2026-10-30 22:58","pubTimestamp":1793372324,"startTime":"0","endTime":"0","summary":"截至2026年10月30日收盘，迪哲医药报收于55.77元，较前一交易日上涨0.7%，最新总市值为259.42亿元。该股当日开盘55.4元，最高57.5元，最低53.82元，成交额达2.78亿元，换手率为1.08%。近日，迪哲医药发布2026年第三季度报告。报告显示，本报告期营业收入为4,246,871,524.03元，较上年同期增长1,736.09%；归属于上市公司股东的净利润为3,849,148,688.39元。年初至报告期末，营业收入为4,769,564,247.74元，同比增长713.50%；归属于上市公司股东的净利润为3,638,775,318.30元。研发投入合计593,244,735.77元，占营业收入比例为12.44%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000057984.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1161","BK1574","688192","159938","BK0239","09939","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679218064","title":"迪哲医药(688192)9月30日股东户数1.34万户，较上期增加3.96%","url":"https://stock-news.laohu8.com/highlight/detail?id=2679218064","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679218064?lang=zh_cn&edition=full","pubTime":"2026-10-30 19:11","pubTimestamp":1793358684,"startTime":"0","endTime":"0","summary":"证券之星消息，近日迪哲医药披露，截至2026年9月30日公司股东户数为1.34万户，较6月30日增加512.0户，增幅为3.96%。在化学制药行业个股中，迪哲医药股东户数低于行业平均水平，截至9月30日，化学制药行业平均股东户数为3.98万户。从股价来看，2026年6月30日至2026年9月30日，迪哲医药区间涨幅为45.28%，在此期间股东户数增加512.0户，增幅为3.96%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026103000046516.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","09939","BK1161","688192","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2679267373","title":"迪哲医药(688192.SH)发布前三季度业绩，归母净利润36.39亿元","url":"https://stock-news.laohu8.com/highlight/detail?id=2679267373","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2679267373?lang=zh_cn&edition=full","pubTime":"2026-10-30 15:46","pubTimestamp":1793346391,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布2026年三季度报告，前三季度，公司实现营业收入47.7亿元，同比增长713.50%。归属于上市公司股东的净利润36.39亿元，归属于上市公司股东的扣除非经常性损益的净利润36.12亿元。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1515988.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["159938","09939","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2678748046","title":"迪哲医药（688192）10月27日主力资金净卖出2748.95万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2678748046","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2678748046?lang=zh_cn&edition=full","pubTime":"2026-10-28 08:46","pubTimestamp":1793148390,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月27日收盘，迪哲医药报收于57.4元，下跌5.98%，换手率1.25%，成交量5.76万手，成交额3.38亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2389.21万元，融资偿还2487.05万元，融资净偿还97.84万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102800014250.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1161","BK1515","BK1574","09939","159938"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677036959","title":"迪哲医药（688192）10月23日主力资金净卖出1111.93万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677036959","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677036959?lang=zh_cn&edition=full","pubTime":"2026-10-24 08:16","pubTimestamp":1792800988,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月23日收盘，迪哲医药报收于63.34元，上涨6.01%，换手率1.55%，成交量7.15万手，成交额4.4亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2991.09万元，融资偿还2789.15万元，融资净买入201.94万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102400006822.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","BK0239","09939","159938","BK1161","BK1515","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2677107266","title":"迪哲医药（688192）10月20日主力资金净卖出1441.66万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2677107266","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2677107266?lang=zh_cn&edition=full","pubTime":"2026-10-21 08:28","pubTimestamp":1792542534,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月20日收盘，迪哲医药报收于61.4元，下跌2.85%，换手率1.23%，成交量5.66万手，成交额3.47亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2784.47万元，融资偿还1852.98万元，融资净买入931.49万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026102100007175.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","09939","159938","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2675951673","title":"迪哲医药（688192）10月13日主力资金净买入348.45万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2675951673","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2675951673?lang=zh_cn&edition=full","pubTime":"2026-10-14 08:14","pubTimestamp":1791936846,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年10月13日收盘，迪哲医药报收于61.9元，上涨7.76%，换手率2.03%，成交量9.37万手，成交额5.64亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2281.94万元，融资偿还3997.64万元，融资净偿还1715.7万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026101400006914.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239","BK1574","159938","BK1161","BK1515","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2670419940","title":"迪哲医药（688192）9月24日主力资金净卖出1437.14万元","url":"https://stock-news.laohu8.com/highlight/detail?id=2670419940","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2670419940?lang=zh_cn&edition=full","pubTime":"2026-09-25 08:23","pubTimestamp":1790295809,"startTime":"0","endTime":"0","summary":"证券之星消息，截至2026年9月24日收盘，迪哲医药报收于56.45元，下跌6.31%，换手率1.41%，成交量6.52万手，成交额3.74亿元。近5日资金流向一览见下表：迪哲医药融资融券信息显示，融资方面，当日融资买入2711.56万元，融资偿还3926.96万元，融资净偿还1215.39万元。迪哲医药主营业务：专注于肿瘤及血液系统疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026092500005096.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","BK1515","09939","BK1161","688192","159938","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2667507699","title":"每周股票复盘：迪哲医药（688192）比瑞替尼治疗DLBCL客观缓解率达47.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2667507699","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2667507699?lang=zh_cn&edition=full","pubTime":"2026-09-13 02:02","pubTimestamp":1789236137,"startTime":"0","endTime":"0","summary":"截至2026年9月11日收盘，迪哲医药报收于53.07元，较上周的57.07元下跌7.01%。本周，迪哲医药9月7日盘中最高价报57.85元。本周关注点公司公告汇总：比瑞替尼治疗r/r DLBCL的II期临床研究结果显示整体客观缓解率达47.6%。公司公告汇总迪哲医药自愿披露，其自主研发的全球首创LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤的II期临床研究结果已在《血液肿瘤期刊》发表。安全性方面可控，未报告药物相关的大出血或房颤事件。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091300000468.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK1574","09939","BK0239","BK1161","688192","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666561405","title":"迪哲医药（688192）披露比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表，9月10日股价下跌0.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=2666561405","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666561405?lang=zh_cn&edition=full","pubTime":"2026-09-10 17:32","pubTimestamp":1789032727,"startTime":"0","endTime":"0","summary":"截至2026年9月10日收盘，迪哲医药报收于54.38元，较前一交易日下跌0.95%，最新总市值为252.96亿元。该股当日开盘54.92元，最高55.45元，最低53.71元，成交额达1.79亿元，换手率为0.71%。迪哲（江苏）医药股份有限公司于近日披露公告，其自主研发的全球首创LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤的II期临床研究结果已在国际权威期刊《血液肿瘤期刊》发表。安全性可控，未报告药物相关的大出血或房颤事件。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026091000031585.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","688192","BK1161","09939","159938","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666583145","title":"迪哲医药(688192.SH)：比瑞替尼治疗弥漫性大B细胞淋巴瘤研究成果获《血液肿瘤期刊》发表","url":"https://stock-news.laohu8.com/highlight/detail?id=2666583145","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2666583145?lang=zh_cn&edition=full","pubTime":"2026-09-09 15:56","pubTimestamp":1788940569,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 发布公告，公司自主研发的全球首创、可完全穿透血脑屏障的非共价LYN/BTK双靶点抑制剂比瑞替尼单药治疗复发/难治弥漫性大B细胞淋巴瘤II期临床研究结果正式发表于国际权威血液学期刊《血液肿瘤期刊》。TAI-SHAN9研究入组患者既往接受过1至5线系统性治疗。研究结果显示，在50mg和75mg剂量下，比瑞替尼单药治疗在不同分子亚型中均展现出广谱的抗肿瘤活性，并呈现出可管理的安全性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1493833.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","BK1161","159938","BK0239","09939","688192","BK1574"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2665567365","title":"每周股票复盘：迪哲医药（688192）舒沃哲一线治疗肺癌适应症获FDA受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2665567365","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2665567365?lang=zh_cn&edition=full","pubTime":"2026-09-06 01:30","pubTimestamp":1788629429,"startTime":"0","endTime":"0","summary":"截至2026年9月4日收盘，迪哲医药报收于57.07元，较上周的58.67元下跌2.73%。本周，迪哲医药9月3日盘中最高价报60.69元。本周关注点来自公司公告汇总：舒沃哲新增适应症上市申请获美国FDA受理，拟用于一线治疗EGFR exon20ins非小细胞肺癌。此前，舒沃哲已获中美两国突破性疗法认定，并已在中美获批用于二线及后线治疗。迪哲医药与阿斯利康签署的《许可协议》已于2026年8月31日正式生效，授权阿斯利康在全球范围内独家开发和商业化舒沃哲。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026090600000251.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["159938","BK0239","09939","688192","BK1161","BK1574","BK1515"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2664881161","title":"迪哲医药(688192.SH)：与阿斯利康就舒沃哲®授权许可协议生效","url":"https://stock-news.laohu8.com/highlight/detail?id=2664881161","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2664881161?lang=zh_cn&edition=full","pubTime":"2026-09-01 08:44","pubTimestamp":1788223497,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年7月14日与AstraZeneca UK Limited(以下简称“阿斯利康”)签署《许可协议》，授予阿斯利康在全球范围内独家开发、商业化舒沃哲®的权利。协议约定的协议生效条件已全部满足，协议于2026年8月31日正式生效。阿斯利康将于今年第四季度在美国实现舒沃哲®商业化。公司将获得阿斯利康支付的一次性、不可返还的首付款6亿美元，最高达4 亿美元的临床开发里程碑款项以及最高达5亿美元的销售里程碑款项，此外公司将获得按舒沃哲®全球销售额最高到低双位数的阶梯式比例的特许权使用费。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1490099.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09939","BK1515","159938","BK1574","688192","BK1161","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663071350","title":"迪哲医药（688192）披露舒沃哲新增适应症上市申请获美国FDA受理，8月31日股价下跌0.66%","url":"https://stock-news.laohu8.com/highlight/detail?id=2663071350","media":"证券之星","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2663071350?lang=zh_cn&edition=full","pubTime":"2026-08-31 17:44","pubTimestamp":1788169497,"startTime":"0","endTime":"0","summary":"截至2026年8月31日收盘，迪哲医药报收于58.28元，较前一交易日下跌0.66%，最新总市值为271.1亿元。该股当日开盘57.87元，最高59.58元，最低57.5元，成交额达3.55亿元，换手率为1.32%。迪哲医药近日披露公告，公司自主研发的舒沃哲新增适应症上市申请已获美国FDA受理，拟用于一线治疗EGFR exon20ins的局部晚期或转移性非小细胞肺癌成人患者。该适应症在中国也已获NMPA受理并纳入优先审评，此前已获中美突破性疗法认定。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026083100024818.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["09939","BK1574","159938","688192","BK1515","BK0239","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662034757","title":"迪哲医药(688192.SH)重新向香港联交所递交H股发行上市申请并刊发申请资","url":"https://stock-news.laohu8.com/highlight/detail?id=2662034757","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2662034757?lang=zh_cn&edition=full","pubTime":"2026-08-28 08:25","pubTimestamp":1787876738,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，公司于2026年8月27日重新向香港联合交易所有限公司(以下简称“香港联交所”)递交了发行H股股票并在香港联交所主板挂牌上市的申请，并于同日在香港联交所网站刊登了本次发行上市的申请材料。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1487677.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","IPOS","BK1515","159938","BK0239","09939","BK1574","688192"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661110862","title":"每周股票复盘：迪哲医药（688192）股东户数增18.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661110862","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661110862?lang=zh_cn&edition=full","pubTime":"2026-08-23 02:53","pubTimestamp":1787424789,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，迪哲医药报收于59.0元，较上周的60.91元下跌3.14%。本周，迪哲医药8月18日盘中最高价报62.65元。公司公告汇总：公司与阿斯利康签署许可协议，授予舒沃哲全球独家开发和商业化权利，获得6亿美元首付款。股本股东变化截至2026年6月30日，公司股东户数为1.29万户，较3月31日增加2041户，增幅18.73%。户均持股数量由上期的4.26万股减少至3.6万股，户均持股市值为143.58万元。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082300000568.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","09939","BK0239","BK1515","159938","BK1574","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2661303296","title":"迪哲医药（688192）披露舒沃哲两项非小细胞肺癌临床研究数据获选2026年世界肺癌大会展示，8月21日股价下跌5.07%","url":"https://stock-news.laohu8.com/highlight/detail?id=2661303296","media":"证券之星","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2661303296?lang=zh_cn&edition=full","pubTime":"2026-08-21 22:15","pubTimestamp":1787321724,"startTime":"0","endTime":"0","summary":"截至2026年8月21日收盘，迪哲医药报收于59.0元，较前一交易日下跌5.07%，最新总市值为274.45亿元。该股当日开盘60.45元，最高61.1元，最低58.1元，成交额达5.38亿元，换手率为1.96%。近日，迪哲医药发布自愿披露公告，其自主研发的舒沃哲两项非小细胞肺癌领域的最新临床研究数据获选在2026年世界肺癌大会上以壁报形式展示。目前相关适应症尚处临床试验阶段，存在不确定性。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026082100045408.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK1574","09939","BK1161","BK1515","159938","BK0239"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2659175175","title":"每周股票复盘：迪哲医药（688192）拟调整董事会人数至7人","url":"https://stock-news.laohu8.com/highlight/detail?id=2659175175","media":"证券之星","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohunote.com/m/news/2659175175?lang=zh_cn&edition=full","pubTime":"2026-08-16 01:50","pubTimestamp":1786816223,"startTime":"0","endTime":"0","summary":"截至2026年8月14日收盘，迪哲医药报收于60.91元，较上周的56.0元上涨8.77%。本周，迪哲医药8月13日盘中最高价报63.66元。迪哲医药当前最新总市值283.33亿元，在化学制药板块市值排名15/149，在两市A股市值排名704/5207。本周关注点公司公告汇总：迪哲医药拟调整董事会人数为7人，并选举第三届董事会成员。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026081600000322.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK1574","09939","159938","688192","BK1161","BK0239","BK1515"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"ret":0,"serverTime":1793858856007,"stockEarnings":[{"period":"1week","weight":0.1033},{"period":"1month","weight":0.105},{"period":"3month","weight":0.2223},{"period":"6month","weight":0.18},{"period":"1year","weight":0.012},{"period":"ytd","weight":0.1128}],"compareEarnings":[{"period":"1week","weight":0.0013},{"period":"1month","weight":-0.0406},{"period":"3month","weight":-0.0549},{"period":"6month","weight":-0.1181},{"period":"1year","weight":-0.0692},{"period":"ytd","weight":-0.0712}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"13448人(较上一季度增加3.96%)","perCapita":"34296股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46516万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是专注于肿瘤、血液系统疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲。公司获第七批国家级专精特新“小巨人”企业认定。此外，公司首款源头创新产品舒沃哲的研发及产业化项目，荣获江苏省科技进步奖一等奖。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"isLaohu8Offline":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.52.0","shortVersion":"4.52.0","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药-U,688192,迪哲医药-U股票,迪哲医药-U股票老虎,迪哲医药-U股票老虎国际,迪哲医药-U行情,迪哲医药-U股票行情,迪哲医药-U股价,迪哲医药-U股市,迪哲医药-U股票价格,迪哲医药-U股票交易,迪哲医药-U股票购买,迪哲医药-U股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药-U(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药-U(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}